News

Trelegy Ellipta, which is a once-daily, single-inhaler triple therapy, was approved by the US Food and Drug Administration (FDA) in late 2017 for the long-term, once-daily maintenance treatment

Pixuvri has approval for the treatment of adult patients having multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma, a type of blood cancer. The drug is a cytotoxic

The global, multicenter, randomized, non-inferiority trial investigated the efficacy and safety of Merck’s antibacterial product RECARBRIO for use in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial

Celltrion anticipates Temixys to be available in the next coming weeks. Temixys (lamivudine and tenofovir disoproxil fumarate) 300mg/300mg is a once-daily combination of two nucleoside reverse transcriptase inhibitors,

The deal to acquire Dova Pharmaceuticals includes an upfront payment of $27.50 (£22.35) per share in cash, as well as one non-tradeable contingent value right (CVR). Dova Pharmaceuticals

There are now four clinical studies evaluating SCB-313 open to recruiting patients in China and Australia across three oncology indications (malignant ascites, peritoneal carcinomatosis, and malignant pleural effusions).

Results showed a statistically significant and clinically meaningful improvement in OS, a key secondary endpoint for Tagrisso versus gefitinib or erlotinib, both of which were previous standard-of-care (SoC)

GPA and MPA are rare and potentially life-threatening diseases, which affect small and medium-sized blood vessels. The FDA approval was based on data from the PePRS phase IIa,

Niraparib delivered the desired result when given as monotherapy in the patient population, irrespective of biomarker status. The results of the PRIMA trial were presented at the 2019